A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Batshaw, Mark L.
Wilson, James M.Note: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationYang, Y., L. Wang, P. Bell, D. McMenamin, Z. He, J. White, H. Yu, et al. 2016. “A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice.” Nature biotechnology 34 (3): 334-338. doi:10.1038/nbt.3469. http://dx.doi.org/10.1038/nbt.3469.
AbstractMany genetic liver diseases present in newborns with repeated, often lethal, metabolic crises. Gene therapy using non-integrating viruses such as AAV is not optimal in this setting because the non-integrating genome is lost as developing hepatocytes proliferate1,2. We reasoned that newborn liver may be an ideal setting for AAV-mediated gene correction using CRISPR/Cas9. Here we intravenously infuse two AAVs, one expressing Cas9 and the other expressing a guide RNA and the donor DNA, into newborn mice with a partial deficiency in the urea cycle disorder enzyme, ornithine transcarbamylase (OTC). This resulted in reversion of the mutation in 10% (6.7% – 20.1%) of hepatocytes and increased survival in mice challenged with a high-protein diet, which exacerbates disease. Gene correction in adult OTC-deficient mice was lower and accompanied by larger deletions that ablated residual expression from the endogenous OTC gene, leading to diminished protein tolerance and lethal hyperammonemia on a chow diet.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29002437
- HMS Scholarly Articles